Retatrutide Diarrhoea: Duration and Side Effects

Retatrutide diarrhoea is among the most commonly reported gastrointestinal adverse events in clinical trial data for this investigational triple hormone receptor agonist. Retatrutide holds no UK marketing authorisation and is accessible only through enrolment in an authorised clinical trial. Published Phase 2 and Phase 3 trial findings indicate that diarrhoea occurred most frequently during dose-escalation periods and was generally described as transient. This article summarises what trial data report about duration and frequency, outlines other gastrointestinal effects observed, and explains when to seek medical advice for persistent symptoms.

What is retatrutide and what is its current status in the UK?

Retatrutide is an investigational triple receptor agonist (GIP, GLP-1 and glucagon) with no UK marketing authorisation; it is accessible only through enrolment in an authorised clinical trial.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and access is only via enrolment in an authorised clinical trial; care and dosing are managed by the research team.^[1][2] It is an investigational triple hormone receptor agonist, acting simultaneously on GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and glucagon receptors. This triple mechanism distinguishes it pharmacologically from currently licensed dual or single agonists, though no authorised head-to-head comparisons exist. Because retatrutide is unlicensed, it cannot be advertised, and no launch date or regulatory timeline can be given.

Clinical investigation has progressed through Phase 2 and into Phase 3, with the TRIUMPH programme evaluating retatrutide in people with obesity and the TRANSCEND programme in people with type 2 diabetes.^[4][5] Phase 2 findings published in the New England Journal of Medicine in 2023 reported on weight reduction and glycaemic outcomes in trial populations over defined study periods.^[2][3] Phase 3 readouts, including data from TRANSCEND-T2D-1 and the TRIUMPH studies, have since been reported at scientific meetings and in peer-reviewed publications, though all results describe outcomes in trial participants under controlled conditions and cannot be generalised to the wider public.

For anyone interested in licensed weight-management treatments, a GP can discuss options that are currently authorised and available on the NHS or privately. No pathway exists to obtain retatrutide outside of participation in an authorised clinical trial, and no date can be given for when, or whether, it will receive a UK marketing authorisation.

How long does diarrhoea typically last in retatrutide trial participants?

Trial data do not provide a precise median duration for diarrhoea episodes, but published findings describe gastrointestinal side effects as generally transient and most frequent during dose escalation.

Based on data reported from Phase 2 and Phase 3 retatrutide trials, diarrhoea was among the most commonly observed gastrointestinal adverse events, and it appeared most frequently during the dose-escalation phase of the study protocol.^[2][3] The available trial data do not provide a precise median duration for individual episodes of diarrhoea, so it is not possible to state a definitive figure for how long it lasts in any given participant. What the published findings indicate is that gastrointestinal side effects, including diarrhoea, were generally described as transient and tended to occur early in treatment, particularly as doses were increased.

This pattern is broadly consistent with what has been observed with other GLP-1 receptor agonist class medicines, where gastrointestinal symptoms often reduce in frequency and severity once the body has adapted to a stable dose.^[7][8] However, because retatrutide is investigational and trial protocols differ from real-world prescribing, these observations apply specifically to the trial populations studied and under the conditions of those trials.

If you are a participant in a retatrutide clinical trial and experience diarrhoea or any other adverse event, you should report this to your trial team promptly and follow the guidance set out in your study protocol. Do not stop or adjust your study medication without first consulting your trial team. Suspected side effects from any medicine can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; however, if you are enrolled in a trial, your primary reporting route is the trial team or sponsor. Anyone who develops severe or prolonged diarrhoea, regardless of cause, should seek prompt medical advice to avoid complications such as dehydration.

What other gastrointestinal side effects have been reported in trials?

Phase 2 and Phase 3 trial data report nausea, vomiting, constipation and abdominal pain as common gastrointestinal adverse events, with nausea being the most frequently reported overall.

Beyond diarrhoea, Phase 2 and Phase 3 retatrutide trial data have reported a range of gastrointestinal adverse events that were common across the active treatment groups. The most frequently reported included:

• Nausea, which was the most commonly reported gastrointestinal event overall^[2][3]

• Vomiting, occurring particularly during dose escalation

• Constipation, which was also noted across multiple dose groups

• Abdominal pain and discomfort

Decreased appetite was also commonly reported in trials. Although it is sometimes considered a desired pharmacological effect rather than a gastrointestinal adverse event, it can contribute to reduced food intake and gastrointestinal discomfort and is worth noting separately.

These findings are consistent with the known pharmacology of GLP-1 receptor agonism, which slows gastric emptying and alters gut motility.^[7][8] The triple receptor mechanism of retatrutide, which additionally engages GIP and glucagon receptors, may influence the overall gastrointestinal tolerability profile, though direct comparisons with licensed medicines are not possible from the available trial data. Gastrointestinal side effects were generally more frequent at higher doses and during escalation periods, and the trial protocols included structured dose-escalation schedules designed to manage tolerability.

The UK SmPC for licensed GLP-1 class medicines notes that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome. While retatrutide is not licensed and has no SmPC, this class-level signal is relevant context for any investigational GLP-1-containing agent. Trial participants who experience severe or persistent abdominal pain, which may radiate to the back and may be accompanied by vomiting, should report this to their trial team immediately and seek urgent medical assessment.

When should you seek medical advice about persistent diarrhoea?

Seek medical advice if diarrhoea has not improved after 48 hours, or sooner if there are signs of dehydration, blood in stools, severe abdominal pain or high fever.

Persistent or severe diarrhoea always warrants medical assessment, regardless of its suspected cause, because of the risk of dehydration, electrolyte imbalance and, in vulnerable individuals, more serious complications. If you are a participant in a retatrutide clinical trial and experience diarrhoea or any other adverse event, you should report this to your trial team promptly and follow the guidance set out in your study protocol.

For adults in a general context, NHS guidance advises seeking medical advice if diarrhoea has not improved after two days (48 hours), or sooner if symptoms are severe.^[10] For children under five years, advice should be sought more promptly, and for babies under one year, the same day.^[10] The following are also recognised triggers for seeking advice:

• Signs of dehydration, including reduced urine output, dizziness, dry mouth or unusual thirst

• Blood or mucus in stools

• Severe abdominal pain accompanying loose stools

• High fever alongside gastrointestinal symptoms

• Diarrhoea in older adults, young children or people with underlying health conditions, where dehydration can develop more rapidly

In these situations, contact your GP in the first instance. If you are unable to reach your GP and symptoms are worsening, NHS 111 can provide urgent advice. Call 999 or go to A&E only if symptoms are life-threatening, for example if someone has collapsed or is showing signs of severe shock.

It is important to maintain adequate fluid intake during any episode of diarrhoea. Oral rehydration solutions, available from pharmacies, can help replace lost fluids and electrolytes. If you are considering an over-the-counter anti-diarrhoeal such as loperamide, do not use it if there is blood or mucus in your stools, if you have a high fever, or if Clostridioides difficile infection is suspected.^[11][12] If you are enrolled in a clinical trial, seek advice from your trial team before using any anti-diarrhoeal, as this may affect trial assessments.

What are the risks of obtaining retatrutide outside of clinical trials?

Retatrutide cannot be legally supplied outside an authorised clinical trial in the UK; informally sourced products may be falsified, contaminated or mislabelled, posing serious and unpredictable health risks.

Retatrutide cannot be legally supplied or prescribed outside of an authorised clinical trial in the UK, and anything sold online or through informal channels as retatrutide is not a licensed product and may be falsified, contaminated or mislabelled. The risks of using such products are serious and unpredictable. Falsified medicines may contain incorrect active ingredients, harmful impurities or no active substance at all, and they are produced without the quality controls required of licensed medicines.^[13] The MHRA publishes public safety advice on falsified and unlicensed medicines at gov.uk/mhra and actively monitors and takes action against unlicensed supply.

Purchasing injectable products from unregulated online sources carries additional risks beyond incorrect dosing, including infection at the injection site, transmission of bloodborne pathogens through non-sterile equipment, and severe allergic reactions.

From a gastrointestinal safety perspective specifically, the dose-escalation schedules used in authorised retatrutide trials are carefully designed and medically supervised to manage tolerability, including the risk of diarrhoea, nausea and vomiting. Outside of a trial, there is no medical oversight, no structured escalation, and no mechanism for reporting or managing adverse events safely.

If you are interested in weight management treatment, the appropriate route is to speak with your GP, who can discuss licensed options and refer you to appropriate services. Participating in a legitimate clinical trial is the only lawful way to access retatrutide in the UK, and eligibility criteria for trials are set by the research teams running them. Members of the public can search for legitimate UK trials through the NIHR Be Part of Research service at bepartofresearch.nihr.ac.uk, or through the clinicaltrials.gov registry.

Scientific References

1. Medicines and Healthcare products Regulatory Agency.
2. Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Jastreboff AM et al.).
3. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Jastreboff AM et al.) [PubMed record].
4. Retatrutide in adults with obesity and type 2 diabetes (Bellido V et al.).
5. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist (Bajaj HS et al.).
6. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial (Rosenstock J et al.).
7. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
8. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
9. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
10. Diarrhoea and vomiting.
11. Clostridioides difficile (C. diff) infection.
12. Clostridioides difficile infection: antimicrobial prescribing (NG199).
13. Application of the Falsified Medicines Directive (safety features).
14. Clinical trials.

Frequently Asked Questions